Sosei Heptares Joins our Customer Community!
September 2022
With offices in Cambridge and London, UK, Sosei Heptares is focused on the discovery and early development of new medicines originating from their proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities.
CRISPR Therapeutics is the latest life science company to select R&D Logic!
May 2022
With offices in Cambridge, MA, San Francisco, CA and Zug Switzerland CRISPR Therapeutics is focused on developing transformative gene-based medicines for serious human diseases.
R&D Logic is proud to welcome Disc Medicine!
April 2022
Located in Watertown, MA, Disc Medicines is committed to building a brighter future for patients. Using new discoveries and insights in hematology, they are advancing the frontiers of biology to create life-changing medicines.
Ensoma Joins the R&D Logic Community!
March 2022
Located in Boston, MA, Ensoma is expanding the boundaries of genetic medicine – from rare monogenic illnesses to prevalent polygenic conditions such as autoimmune disease and cancer that affect millions around the world.